Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EPS (Basic) (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed EPS (Basic) for 15 consecutive years, with $0.01 as the latest value for Q2 2025.

  • On a quarterly basis, EPS (Basic) rose 104.49% to $0.01 in Q2 2025 year-over-year; TTM through Jun 2025 was $0.01, a 100.44% increase, with the full-year FY2025 number at -$2.16, up 4.42% from a year prior.
  • EPS (Basic) was $0.01 for Q2 2025 at Aytu Biopharma, up from -$0.22 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $28.7 in Q2 2022 to a low of -$21.76 in Q3 2021.
  • A 5-year average of -$0.81 and a median of -$0.64 in 2021 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): tumbled 6117.14% in 2021, then skyrocketed 3827.27% in 2022.
  • Aytu Biopharma's EPS (Basic) stood at -$8.54 in 2021, then skyrocketed by 74.82% to -$2.15 in 2022, then soared by 98.14% to -$0.04 in 2023, then tumbled by 450.0% to -$0.22 in 2024, then skyrocketed by 104.49% to $0.01 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EPS (Basic) are $0.01 (Q2 2025), -$0.22 (Q2 2024), and -$0.52 (Q1 2024).